Xi'an Disai Biological Pharmaceutical

Xi'an Disai Biological Pharmaceutical is a prominent Chinese pharmaceutical enterprise focused on the development and manufacturing of biochemical and immunomodulatory medicines. Established in 1992 and headquartered in the Xi'an High-tech Industries Development Zone, the company has become a leader in the production of thymic peptide-based therapies. Its flagship product, Disai (Thymopolypeptides Injection), is widely utilized in China for treating immune dysfunction, chronic hepatitis B, and as a supportive treatment for cancer patients undergoing chemotherapy. The company's manufacturing facilities are GMP-certified, supporting a diverse portfolio that includes injections, capsules, and tablets. Xi'an Disai continues to invest in the research of biochemical drugs to address unmet needs in infectious diseases and oncology. Through its established distribution network, the company maintains a strong commercial presence across the Chinese domestic healthcare market.